Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Angina V: Nursing Management

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Compliance to genomic test recommendations to guide adjuvant chemotherapy decision-making in the case of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, in real-life settings.

Cancer medicine·2023

Same author

Psychometric properties of the French Hot Flash Related Daily Interference Scale (HFRDIS).

Climacteric : the journal of the International Menopause Society·2022

Same author

Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study.

ESMO open·2021

Same author

HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer.

ESMO open·2021

Same author

Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort<sup>☆</sup>.

ESMO open·2021

Same author

Prosigna test in breast cancer: real-life experience.

Breast cancer research and treatment·2021

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Motility of Single Molecules and Clusters of Bi-Directional Kinesin-5 Cin8 Purified from S. cerevisiae Cells

Motility of Single Molecules and Clusters of Bi-Directional Kinesin-5 Cin8 Purified from S. cerevisiae Cells

Published on: February 2, 2022

[Management of CIN1].

¹Service de Gynécologie-Obstétrique, Hôpital Tenon, Université Pierre-et-Marie-Curie, Paris-VI, Paris, France. rouzierroman@yahoo.fr

Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction

|January 15, 2008

Summary

Cervical intraepithelial neoplasia grade 1 (CIN1) often regresses spontaneously. Current management guidelines aim to reduce overtreatment by recommending strict follow-up rather than immediate intervention for CIN1, utilizing new diagnostic tests for better patient outcomes.

Area of Science:

Gynecology
Oncology
Pathology

Context:

Cervical intraepithelial neoplasia grade 1 (CIN1) management faces challenges due to overtreatment and practice variability.
Existing 2002 recommendations for CIN1 may lead to unnecessary interventions.
Advancements in diagnostic testing necessitate updated clinical guidelines.

Purpose:

To review and update recommendations for managing CIN1 based on current evidence.
To evaluate the natural history and progression risk of CIN1.
To assess the utility of new diagnostic tests, including HPV testing, in CIN1 management.

Summary:

CIN1, a precancerous lesion, spontaneously regresses in over 60% of cases within two years.
The risk of CIN1 progressing to CIN3 or higher is less than 9% within two years.

Related Experiment Videos

Last Updated: Jul 8, 2026

Motility of Single Molecules and Clusters of Bi-Directional Kinesin-5 Cin8 Purified from S. cerevisiae Cells

Motility of Single Molecules and Clusters of Bi-Directional Kinesin-5 Cin8 Purified from S. cerevisiae Cells

Published on: February 2, 2022

Newer diagnostic approaches, including HPV testing, offer improved sensitivity and reduced colposcopy referrals for CIN1 follow-up.

Strict follow-up with colposcopy and treatment reserved for persistent or progressive abnormalities is recommended for CIN1.

Impact:

Updated guidelines aim to minimize overtreatment of CIN1, reducing patient anxiety and healthcare costs.
Integration of HPV testing into follow-up protocols can enhance diagnostic accuracy and patient management.
Revised management strategies for CIN1 are expected to improve clinical practice consistency and patient outcomes.